ACCOUNTS - Final Accounts preparation

ACCOUNTS - Final Accounts preparation


Caseware UK (AP4) 2021.0.152 2021.0.152 2021-03-312021-03-31false2020-04-20trueNo description of principal activity1 12567151 2020-04-19 12567151 2020-04-20 2021-03-31 12567151 2019-04-20 2020-04-19 12567151 2021-03-31 12567151 c:Director1 2020-04-20 2021-03-31 12567151 c:EntityHasNeverTraded 2020-04-20 2021-03-31 12567151 c:Micro-entities 2020-04-20 2021-03-31 12567151 c:AuditExempt-NoAccountantsReport 2020-04-20 2021-03-31 12567151 c:FullAccounts 2020-04-20 2021-03-31 12567151 c:PrivateLimitedCompanyLtd 2020-04-20 2021-03-31 iso4217:GBP xbrli:pure

Registered number: 12567151









EXC3 LIMITED 
(FORMERLY KNOWN AS EXCALIBUR COVID VACCINES LTD)







DORMANT

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 31 MARCH 2021

 
EXC3 LIMITED
REGISTERED NUMBER: 12567151

BALANCE SHEET
AS AT 31 MARCH 2021

2021
£


Current assets
1

Net current assets
 
 
1

Total assets less current liabilities
1


Net assets
1



Capital and reserves
1


Notes

General information

EXC3 Limited is a private limited company, incorporated in England and Wales, registered number 12819096. The address of the registered office is 2nd Floor, 60 St James's Street, St James's, London, United Kingdom, SW1A 1LE.




Average number of employees

The average monthly number of employees, including directors, during the period was 1.




The Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

The members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities' regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 29 March 2022.




Professor Christopher Thomas Evans
Director

Page 1